parkinson, Parkinson's research notebook

Six readers

reader	found	score
genetics Open Targets	no genetic evidence; overall 0.33 from other evidence	0.00
cell type Human Protein Atlas	cell type enhanced, including oligodendrocyte progenitor cells; strongest in ependymal cells	0.75
chemistry Open Targets	a small-molecule pocket	0.60
trials ClinicalTrials.gov	no Parkinson's trials on record: an open field	1.00
literature PubMed	no papers tie it to Parkinson's yet	1.00
pathways Reactome	in no curated pathway	0.00

No case: the score is under the bar. Receipt 1048

receipt 1055: NME9 in dopamine neurons, braak

power: full sample +0.04 (p 0.881, n 18), 95% CI -0.44 to +0.50. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: -0.09 (p 0.709, n 18). does not hold up.
composition: dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.09 (p 0.709, n 18). could be the mix.
skeptic: leave-one-out range -0.06 to +0.17, sign flips 6; without severely affected donors +0.04 (p 0.881, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for NME9 in dopamine neurons.

case closed: nothing better to follow up.

receipt 1054: NME9 in oligodendrocytes, braak

power: full sample -0.09 (p 0.709, n 18), 95% CI -0.54 to +0.39. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: -0.09 (p 0.709, n 18). does not hold up.
composition: oligodendrocytes share of nuclei vs axis +0.03 (p 0.915); controlling for it: -0.09 (p 0.722, n 18). could be the mix.
skeptic: leave-one-out range -0.17 to +0.04, sign flips 3; without severely affected donors -0.09 (p 0.709, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for NME9 in oligodendrocytes.

case closed: nothing better to follow up.

loading the receipts